Eplontersen Missed Its ATTR-CM Phase 3 Endpoint: What HR 0.71 Does—and Does Not—Mean

원문 링크: WordPress 원문

ENGKOR

A Phase 3 trial can miss its main endpoint and still contain a signal worth studying. The difficult part is not turning that signal into a second, unofficial victory.

That is the situation with CARDIO-TTRansform, the AstraZeneca–Ionis trial of eplontersen in transthyretin amyloid cardiomyopathy, or ATTR-CM.

The trial did not show a statistically significant benefit on its primary endpoint in the overall population. A prespecified subgroup produced a nominally significant hazard ratio of 0.71. Both statements are true, but they do not carry equal evidentiary weight.

If you remember only one thing

The overall Phase 3 result was negative. The HR 0.71 subgroup is a reason to examine the complete data—not evidence that the trial was positive after all.

What CARDIO-TTRansform tested

ATTR-CM develops when misfolded transthyretin, or TTR, accumulates as amyloid in the heart. The deposits make the heart stiffer and can contribute to progressive heart failure.

Eplontersen is a GalNAc-conjugated antisense oligonucleotide. It reaches liver cells and promotes degradation of both variant and wild-type TTR messenger RNA, reducing production of circulating TTR protein.

CARDIO-TTRansform was a global, randomized, double-blind, placebo-controlled Phase 3 study. Participants received eplontersen 45 mg or placebo by subcutaneous injection every four weeks while continuing available standard care. The primary endpoint combined cardiovascular death with recurrent cardiovascular clinical events through Week 140.

AstraZeneca and Ionis reported 1,432 enrolled participants across 130 sites in 20 countries. The current ClinicalTrials.gov record lists actual enrollment as 1,438. The reason for this small discrepancy is not public, so the exact analyzed population should wait for the full presentation.

The overall trial missed its primary endpoint

On July 9, AstraZeneca and Ionis reported that adding eplontersen did not provide a statistically significant benefit on the primary composite endpoint in the overall population.

This is the trial’s main result. It should not be replaced by a favorable biomarker, imaging measure, or subgroup after the fact.

The companies also said that several secondary, imaging, and biomarker analyses favored eplontersen and that TTR levels fell substantially. Those findings may help explain biological activity, but the numerical results have not yet been released. Lowering TTR is not automatically the same as reducing cardiovascular deaths or clinical events.

The safety profile was described as favorable and consistent with earlier experience. Detailed adverse-event rates were not disclosed in the topline announcement.

Why background stabilizer treatment matters

The study began in 2020, while ATTR-CM treatment was changing quickly. TTR stabilizers such as tafamidis aim to keep the circulating TTR tetramer from falling apart. Eplontersen works farther upstream by reducing TTR production in the liver.

At baseline, 57% of participants in each arm were already receiving a stabilizer. A further 24% in each arm started a stabilizer during the trial.

That means the study was not simply eplontersen versus no active ATTR therapy. For much of the population, it asked whether adding a silencer could provide further benefit on top of contemporary care.

In participants who were receiving a stabilizer at baseline, the companies reported no treatment effect. This means CARDIO-TTRansform did not establish added benefit in that subgroup. It does not prove that every stabilizer–silencer combination will always fail; that broader claim would require more evidence.

Conceptual illustration

Conceptual illustration of the two intervention points. It does not represent a measured CARDIO-TTRansform result or demonstrate combination efficacy.

What does HR 0.71 mean here?

In the prespecified subgroup described by the companies as eplontersen monotherapy, the primary composite endpoint produced a hazard ratio of 0.71 and was nominally significant.

This is potentially important, but four limits must stay attached to the number.

• The overall primary endpoint was not met. A subgroup does not overturn the trial’s primary statistical conclusion.

• “Nominally significant” is not the same as a multiplicity-controlled confirmatory result. The release did not provide the confidence interval, exact p value, or full testing hierarchy.

• It is a composite recurrent-event endpoint. HR 0.71 should not be translated as “29% lower mortality,” “29% fewer patients had events,” or “29% more effective.”

• The subgroup needs a precise definition. The release contrasts monotherapy with stabilizer use at baseline, but 24% of each arm started a stabilizer during follow-up. The handling of those later starts is not yet clear.

The correct reading is therefore cautious: patients not on stabilizer therapy at baseline may have shown a favorable signal, but its size, robustness, and regulatory meaning cannot be judged from the press release alone.

This is not a failure of the entire RNA-silencing class

Eplontersen is one RNA-targeted medicine, and CARDIO-TTRansform is one trial in a rapidly changing treatment setting.

Another TTR silencer, vutrisiran, showed a significant benefit on the composite of all-cause mortality and recurrent cardiovascular events in the HELIOS-B Phase 3 trial. The U.S. FDA subsequently approved AMVUTTRA for adult ATTR-CM in March 2025. That does not prove eplontersen should work, but it does show that the CARDIO-TTRansform result cannot be generalized into “RNA silencers do not work in ATTR-CM.”

Cross-trial comparisons also have limits. CARDIO-TTRansform and HELIOS-B used different molecules, enrolled different populations, and were conducted across an evolving standard-of-care landscape. Their subgroup results should not be compared as if the trials were head-to-head.

WAINUA’s existing approval is for a different manifestation

Eplontersen is already marketed as WAINUA in the United States for adults with the polyneuropathy of hereditary transthyretin-mediated amyloidosis, or ATTRv-PN.

That approval is based on a neurologic disease manifestation and a different clinical program. CARDIO-TTRansform tested cardiomyopathy. Missing the ATTR-CM endpoint does not cancel the approved ATTRv-PN indication, and the ATTRv-PN approval does not establish efficacy in ATTR-CM.

Keeping the organ manifestation and indication visible prevents two opposite errors: declaring the entire drug invalid, or assuming an existing approval automatically extends to the heart.

What the full presentation needs to answer

AstraZeneca and Ionis said they plan to present the full results at the European Society of Cardiology Congress in August 2026. The most useful details will be:

• the overall hazard ratio, confidence interval, exact p value, and event counts;

• cardiovascular death and recurrent-event components separately;

• the exact definition and size of the monotherapy subgroup;

• how stabilizer initiation during follow-up was handled;

• the baseline-stabilizer subgroup estimate and confidence interval;

• six-minute walk distance and KCCQ quality-of-life results;

• imaging and biomarker values rather than direction alone; and

• complete safety, discontinuation, and mortality tables.

Until then, the narrow conclusion is the reliable one: CARDIO-TTRansform missed its primary endpoint in the overall ATTR-CM population. HR 0.71 is an interesting prespecified subgroup signal, not an approval-level result and not a rescue of the overall trial.

Sources

• Ionis SEC Exhibit 99.1, 9 July 2026

• AstraZeneca CARDIO-TTRansform update

• CARDIO-TTRansform registry: NCT04136171

• FDA prescribing information for WAINUA

• HELIOS-B publication: PMID 39213194

• FDA prescribing information for AMVUTTRA, including ATTR-CM

This article is for scientific and educational information only. It is not medical advice or investment advice. Treatment decisions should be made with qualified healthcare professionals.